Acceptance and commitment therapy in improving quality of life in motor neuron disease

Affiliations

Comment

Susanne Petri. Lancet. 2024.

. 2024 Jun 1;403(10442):2350-2351.

doi: 10.1016/S0140-6736(24)00753-0. Epub 2024 May 9.

¹ Department of Neurology, Hannover Medical School, Hannover 30625, Germany. Electronic address: petri.susanne@mh-hannover.de.

No abstract available

Conflict of interest statement

I report consulting fees from Amylyx, Biogen, Roche, Zambon, ITF Pharma, and Ferrer.

Acceptance and Commitment Therapy plus usual care for improving quality of life in people with motor neuron disease (COMMEND): a multicentre, parallel, randomised controlled trial in the UK.
Gould RL, McDermott CJ, Thompson BJ, Rawlinson CV, Bursnall M, Bradburn M, Kumar P, Turton EJ, White DA, Serfaty MA, Graham CD, McCracken LM, Goldstein LH, Al-Chalabi A, Orrell RW, Williams T, Noad R, Baker I, Faull C, Lambert T, Chhetri SK, Ealing J, Hanratty A, Radunovic A, Gunawardana N, Meadows G, Gorrie GH, Young T, Lawrence V, Cooper C, Shaw PJ, Howard RJ; COMMEND Collaboration Group. Gould RL, et al. Lancet. 2024 Jun 1;403(10442):2381-2394. doi: 10.1016/S0140-6736(24)00533-6. Epub 2024 May 9. Lancet. 2024. PMID: 38735299 Clinical Trial.